Musculoskeletal Disorders Drugs Market Global Report 2017

The musculoskeletal system drugs market covers medications used in the treatment of musculoskeletal diseases such as arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus, and other musculoskeletal diseases. Some of the major drugs in the market include Humira, Remicade, Brineura, Tymlos (abaloparatide), and Enbrel.

The global musculoskeletal disorders drugs market was estimated to be around $121 billion as of 2016. The musculoskeletal disorders drugs market made up around 11% of the overall pharmaceuticals market in 2016. The musculoskeletal disorders drugs market was the fourth largest market in the global pharmaceutical market in 2016.

New Product Approvals
The product approvals of new musculoskeletal drugs by regulatory bodies is a significant positive trend being witnessed by the market in recent years. For instance, in April 2017, BioMarin received FDA approval for its Brineura (cerliponase alfa) drug that is used for the treatment of late infantile neuronal ceroid lipofuscinosis type 2. In May 2017, Sanofi received FDA approval for its Kevzara drug that is used in the treatment of active rheumatoid arthritis.

1. Musculoskeletal Disorders Drugs Market Characteristics;

2. Musculoskeletal Disorders Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Musculoskeletal Disorders Drugs Market Customer Information;

5. Musculoskeletal Disorders Drugs Market Segmentation;
5.1. Global Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 5.2. Global Musculoskeletal Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Musculoskeletal Disorders Drugs Market Trends And Strategies;

6. Musculoskeletal Disorders Drugs Market Regional And Country Analysis;
6.1. Global Musculoskeletal Disorders Drugs Market, 2016, By Region; 6.2. Global Musculoskeletal Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Musculoskeletal Disorders Drugs Market, 2016, By Country; 6.4. Musculoskeletal Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country;


7. Global Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors;
7.1. Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, Global;

8. Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, By Country;

9. Musculoskeletal Disorders Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Musculoskeletal Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Musculoskeletal Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Rheumatoid Arthritis, 2015, By Country; 9.10. Global Number Of General Practitioners 2016, By Country; 9.11. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Musculoskeletal Disorders Drugs Market;
10.1.1. Asia-Pacific Musculoskeletal Disorders Drugs Market Overview; 10.1.2. Asia-Pacific Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.2. Asia-Pacific Musculoskeletal Disorders Drugs Market: Country Analysis; 10.3. China Musculoskeletal Disorders Drugs Market; 10.3.1. China Musculoskeletal Disorders Drugs Market Overview; 10.3.2. China Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 10.3.3. China Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 10.3.4. China Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.3.5. China Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020; 10.4. India Musculoskeletal Disorders Drugs Market; 10.4.1. India Musculoskeletal Disorders Drugs Market Overview; 10.4.2. India Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 10.4.3. India Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 10.4.4. India Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.4.5. India Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020; 10.5. Japan Musculoskeletal Disorders Drugs Market; 10.5.1. Japan Musculoskeletal Disorders Drugs Market Overview; 10.5.2. Japan Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.5.5. Japan Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020; 10.6. Australia Musculoskeletal Disorders Drugs Market; 10.6.1. Australia Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.6.4. Australia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020;

11. Western Europe Musculoskeletal Disorders Drugs Market;
11.1.1. Western Europe Musculoskeletal Disorders Drugs Market Overview; 11.1.2. Western Europe Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.2. Western Europe Musculoskeletal Disorders Drugs Market: Country Analysis; 11.3. UK Musculoskeletal Disorders Drugs Market; 11.3.1. UK Musculoskeletal Disorders Drugs Market Overview; 11.3.2. UK Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 11.3.3. UK Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.3.5. UK Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020; 11.4. Germany Musculoskeletal Disorders Drugs Market; 11.4.1. Germany Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.4.4 Germany Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020; 11.5 France Musculoskeletal Disorders Drugs Market; 11.5.1 France Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 11.5.2 France Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 11.5.3 France Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.5.4 France Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020; 11.6. Italy Musculoskeletal Disorders Drugs Market; 11.6.1. Italy Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 11.6.2. Italy Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.6.4. Italy Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020; 11.7. Spain Musculoskeletal Disorders Drugs Market; 11.7.1. Spain Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.7.4. Spain Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020;

12. Eastern Europe Musculoskeletal Disorders Drugs Market;
12.1.1. Eastern Europe Musculoskeletal Disorders Drugs Market Overview; 12.1.2. Eastern Europe Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 12.2. Eastern Europe Musculoskeletal Disorders Drugs Market: Country Analysis; 12.3. Russia Musculoskeletal Disorders Drugs Market; 12.3.1. Russia Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 12.3.4. Russia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020;

13. North America Musculoskeletal Disorders Drugs Market;
13.1.1. North America Musculoskeletal Disorders Drugs Market Overview; 13.1.2. North America Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 13.1.3. North America Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 13.2. North America Musculoskeletal Disorders Drugs Market: Country Analysis; 13.3. USA Musculoskeletal Disorders Drugs Market; 13.3.1. USA Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 13.3.2. USA Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 13.3.4. USA Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020;

14. South America Musculoskeletal Disorders Drugs Market;
14.1.1. South America Musculoskeletal Disorders Drugs Market Overview; 14.1.2. South America Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 14.1.3. South America Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 14.2. South America Musculoskeletal Disorders Drugs Market: Country Analysis; 14.3. Brazil Musculoskeletal Disorders Drugs Market; 14.3.1. Brazil Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 14.3.4. Brazil Musculoskeletal Disorders Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012 - 2020;

15. Middle East Musculoskeletal Disorders Drugs Market;
15.1.1. Middle East Musculoskeletal Disorders Drugs Market Overview; 15.1.2. Middle East Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ;

16. Africa Musculoskeletal Disorders Drugs Market;
16.1.1. Africa Musculoskeletal Disorders Drugs Market Overview; 16.1.1. Africa Musculoskeletal Disorders Drugs Market Overview; 16.1.2. Africa Musculoskeletal Disorders Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Musculoskeletal Disorders Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ;

17. Musculoskeletal Disorders Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Abbvie; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Amgen; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Johnson & Johnson; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. F. Hoffmann-La Roche Ltd; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Pfizer Inc.; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Musculoskeletal Disorders Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer